Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Sun Pharma has committed Rs. 100 crores towards these initiatives
Subscribe To Our Newsletter & Stay Updated